JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Modafinil Effects on EEG Biomarkers of Reward and Motivation

  NCT03616717

  Condition:   Healthy Adults
  Interventions:   Drug: Modafinil;   Drug: placebo
  Sponsor:   University of California, San Diego
  Recruiting
• The Pride Body Project

  NCT03451513

  Conditions:   Eating Disorder;   Body Image
  Interventions:   Behavioral: Pride Body Project;   Behavioral: Media Advocacy
  Sponsors:   San Diego State University;   National Institute on Minority Health and Health Disparities (NIMHD)
  Recruiting
• Effects of Negative Affect in Individuals With Binge Eating Episodes

  NCT03393039

  Conditions:   Bulimia Nervosa;   Binge-Eating Disorder;   Obesity;   Eating Disorder
  Intervention:   Behavioral: Negative Affect Task
  Sponsors:   University of California, San Diego;   Sanford Research;   University of Colorado, Denver
  Recruiting
• Cognitive Training for PTSD

  NCT03316196

  Condition:   Posttraumatic Stress Disorder
  Interventions:   Behavioral: COGENT COGNITIVE TRAINING;   Behavioral: Non training computer condition
  Sponsor:   VA Office of Research and Development
  Recruiting
• Managing MTBI-related Headaches With rTMS

  NCT03314584

  Condition:   Traumatic Brain Injury (TBI)
  Interventions:   Device: Transcranial Magnetic Stimulation;   Device: Sham Transcranial Magnetic Stimulation
  Sponsor:   VA Office of Research and Development
  Recruiting
• Enhancement of PTSD Treatment With Computerized Executive Function Training

  NCT03260127

  Condition:   Posttraumatic Stress Disorder
  Interventions:   Behavioral: Computerized executive function training plus CPT (CEFT-CPT);   Behavioral: Word game training plus CPT (WT-CPT)
  Sponsor:   VA Office of Research and Development
  Recruiting
• CBT-I for Veterans With TBI

  NCT02658669

  Conditions:   Insomnia;   Traumatic Brain Injury
  Interventions:   Behavioral: Cognitive-Behavioral Therapy for Insomnia;   Behavioral: Sleep Education
  Sponsor:   VA Office of Research and Development
  Recruiting
• Perioperative Mirror Therapy and Phantom Limb Pain

  NCT02383979

  Conditions:   Phantom Limb Pain;   Phantom Pain;   Phantom Sensation;   Pseudomelia
  Interventions:   Device: Sham (Comparator) Plasma Ball;   Device: Mirror
  Sponsor:   United States Naval Medical Center, San Diego
  Recruiting
• Phase 1, for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities

  NCT04167553

  Condition:   Obese or Overweight Subjects With Comorbidities
  Interventions:   Drug: HM15136;   Drug: Placebo
  Sponsor:   Hanmi Pharmaceutical Company Limited
  Recruiting
• A Prospective, Study Evaluating the Efficacy of DOSE Formulations in Treatment of Melasma and Cutaneous Signs of Aging

  NCT04137263

  Condition:   Melasma
  Intervention:   Other: DOSE formulation
  Sponsors:   Goldman, Butterwick, Fitzpatrick and Groff;   SkinCeuticals
  Recruiting
• Epidermal Adhesive Sensors to Enhance Continuous Glucose Measurement in Patients With Diabetes: The EASE Study

  NCT04088201

  Condition:   Diabetes Mellitus
  Intervention:   Device: Glucose measurements
  Sponsor:   University of California, San Diego
  Recruiting
• Evaluation of the Effects of a Rehabilitation Program in Individuals With Spine Pain

  NCT04081896

  Conditions:   Neck Pain;   Low Back Pain;   Scoliosis;   Thoracic Injuries
  Intervention:   Other: Exercise
  Sponsors:   SpineZone Medical Fitness, Inc;   University of California, San Diego
  Recruiting
• SMILE (Small Incision Lenticule Extraction) in the DoD (Department of Defense)

  NCT04072289

  Conditions:   Myopia;   Astigmatism
  Intervention:   Device: Visumax spherocylindrical treatment
  Sponsors:   United States Naval Medical Center, San Diego;   Carl Zeiss Meditec, Inc.
  Recruiting
• Video Education for Prenatal Testing Choices

  NCT04062968

  Condition:   Pregnancy
  Intervention:   Other: Video education
  Sponsor:   United States Naval Medical Center, San Diego
  Recruiting
• Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat

  NCT04054011

  Condition:   Adiposity
  Intervention:   Drug: Deoxycholic Acid
  Sponsor:   University of California, San Diego
  Recruiting
• Uqora Supplements in Women With UTIs

  NCT04024046

  Condition:   Urinary Tract Infections
  Interventions:   Dietary Supplement: Uqora;   Dietary Supplement: Group1;   Dietary Supplement: Group 2
  Sponsors:   Hawthorne Effect Inc.;   Uqora, Inc.
  Recruiting
• Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx

  NCT03986671

  Conditions:   Obstructive Sleep Apnea;   Amyotrophic Lateral Sclerosis;   Muscular Dystrophies;   Healthy
  Intervention:   Device: Transmembrane EMG Oropharynx Probe
  Sponsor:   Powell Mansfield Inc.
  Recruiting
• Compassion Meditation for Older Adults

  NCT03964246

  Condition:   Anxiety and Mood Disorders
  Interventions:   Behavioral: Compassion Meditation (CM) intervention;   Other: Heathy Aging Psychoeducation
  Sponsor:   VA Office of Research and Development
  Recruiting
• Vagal Nerve Stimulation to Probe Inflammation and Brain in Post-traumatic Stress

  NCT03858985

  Condition:   Post-traumatic Stress
  Interventions:   Device: Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator);   Device: Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)
  Sponsor:   VA Office of Research and Development
  Recruiting
• Evaluation of an Incentive-based Intervention to Improve 90-day Adherence in PAP-Naive Patients

  NCT03851094

  Condition:   Obstructive Sleep Apnea
  Intervention:   Behavioral: Wellth app
  Sponsors:   ResMed;   Wellth Inc.
  Recruiting
• Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

  NCT03817190

  Condition:   Atopic Dermatitis
  Interventions:   Drug: DS107;   Drug: Placebo
  Sponsor:   DS Biopharma
  Recruiting
• Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

  NCT03703856

  Condition:   Alzheimer Disease
  Interventions:   Drug: Memantine;   Drug: Placebo
  Sponsor:   University of California, San Diego
  Recruiting
• Acceptance and Commitment Therapy for Aging People Living With HIV in Chronic Pain

  NCT03699020

  Conditions:   HIV/AIDS;   Chronic Pain
  Interventions:   Behavioral: Acceptance and Commitment Therapy (ACT);   Other: Chronic Pain Education
  Sponsors:   University of California, San Diego;   National Institute on Aging (NIA)
  Recruiting
• Alzheimer Prevention Trials (APT) Webstudy

  NCT03638583

  Conditions:   Alzheimer Disease;   Dementia
  Intervention:  
  Sponsors:   University of Southern California;   National Institute on Aging (NIA);   Brigham and Women's Hospital;   The Cleveland Clinic
  Recruiting
• Obstructive Sleep Apnea Endotypes and Impact on Phenotypes of People Living With HIV

  NCT03575143

  Conditions:   Human Immunodeficiency Virus;   Obstructive Sleep Apnea
  Intervention:  
  Sponsor:   University of California, San Diego
  Recruiting
• Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

  NCT03568058

  Condition:   Advanced Cancer
  Interventions:   Drug: personalized vaccine;   Drug: Pembrolizumab
  Sponsor:   Ezra Cohen
  Recruiting
• Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity

  NCT03553654

  Condition:   Neoplasms
  Intervention:   Diagnostic Test: low dose CT
  Sponsor:   University of California, San Diego
  Recruiting
• Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

  NCT03551002

  Conditions:   Hepatitis C;   Hepatitis C, Chronic;   HIV/AIDS
  Intervention:  
  Sponsor:   University of California, San Diego
  Recruiting
• Self-Management of Continuous Positive Airway Pressure Settings

  NCT03536572

  Condition:   Obstructive Sleep Apnea
  Intervention:   Behavioral: Sleep Apnea Self-Management Program
  Sponsor:   VA Office of Research and Development
  Recruiting
• Cannabidiol and Prolonged Exposure

  NCT03518801

  Condition:   PTSD
  Interventions:   Behavioral: Prolonged Exposure;   Drug: Cannabidiol;   Drug: placebo
  Sponsors:   VA Office of Research and Development;   University of California, San Diego
  Recruiting
• Yoga and Physical Activity for Veterans

  NCT03509909

  Condition:   PTSD
  Interventions:   Behavioral: Hatha yoga;   Behavioral: Supportive physical activity
  Sponsor:   VA Office of Research and Development
  Recruiting
• Physical Therapy for Anal Incontinence

  NCT03252951

  Conditions:   Anal Incontinence;   Fecal Incontinence
  Interventions:   Behavioral: Eccentric Training;   Behavioral: Concentric Training;   Behavioral: Isometric Training;   Behavioral: Biofeedback
  Sponsors:   San Diego State University;   University of California, San Diego
  Recruiting
• A Prospective Trial of Behavioral Therapy for Chronic Cough

  NCT03235466

  Condition:   Cough
  Interventions:   Behavioral: Voice Therapy;   Behavioral: Voice Therapy and Heart Rate Variability Biofeedback;   Behavioral: Heart Rate Variability Biofeedback
  Sponsor:   University of California, San Diego
  Recruiting
• Topiramate and Prolonged Exposure

  NCT03176953

  Condition:   PTSD and Alcohol Use Disorder
  Interventions:   Drug: topiramate;   Behavioral: prolonged exposure;   Drug: placebo
  Sponsors:   VA Office of Research and Development;   University of California, San Diego
  Recruiting
• The Pathogenesis of OSA in People Living With HIV

  NCT03064204

  Conditions:   Obstructive Sleep Apnea;   HIV/AIDS
  Intervention:  
  Sponsors:   University of California, San Diego;   Center For AIDS Research Creative and Novel Ideas in HIV Research (CFAR CNIHR)
  Recruiting
• Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study)

  NCT02774642

  Conditions:   Posttraumatic Stress Disorders;   Chronic Insomnia
  Interventions:   Behavioral: CBTI-PE;   Behavioral: Hygiene-PE
  Sponsor:   VA Office of Research and Development
  Recruiting
• Cognitive-Behavioral Conjoint Therapy (CBCT) Project

  NCT02720016

  Condition:   Post Traumatic Stress Disorder
  Interventions:   Behavioral: CBCT-Home Based (CBCT-HB);   Behavioral: CBCT-Office Based (CBCT-OB);   Behavioral: PTSD Family Education (PFE)
  Sponsor:   VA Office of Research and Development
  Recruiting
• Perturbing of HIV Reservoir With Immune Stimulation

  NCT02707692

  Conditions:   AIDS;   HIV
  Interventions:   Biological: Fluarix;   Biological: Pneumovax;   Other: Placebo
  Sponsors:   University of California, San Diego;   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• OTIS Vedolizumab Pregnancy Exposure Registry

  NCT02678052

  Conditions:   Colitis, Ulcerative;   Crohn's Disease
  Interventions:   Drug: Vedolizumab;   Biological: Other Biological Agent
  Sponsor:   Takeda
  Recruiting
• Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes

  NCT02650024

  Conditions:   Hepatitis C;   Human Immunodeficiency Virus
  Intervention:  
  Sponsor:   University of California, San Diego
  Recruiting
• Efficacy of ART to Interrupt HIV Transmission Networks

  NCT02528773

  Condition:   HIV
  Intervention:  
  Sponsor:   University of California, San Diego
  Recruiting
• Cognitive Rehab and Exposure Treatment for Hoarding

  NCT02402647

  Condition:   Hoarding Disorder
  Interventions:   Behavioral: CREST;   Behavioral: ET
  Sponsor:   VA Office of Research and Development
  Recruiting
• Effects of Watermelon Consumption on Satiety and Digestive Health

  NCT04096586

  Condition:   Satiety
  Interventions:   Other: Red juice;   Other: Watermelon juice
  Sponsor:   San Diego State University
  Recruiting
• Transoral Daytime Neuromuscular Electrical Stimulation in Patients With Simple Snoring

  NCT03913494

  Conditions:   Sleep Apnea, Obstructive;   Sleep Apnea;   Sleep;   Snoring
  Intervention:   Device: Transoral Neurostimulation Device (Snoozeal)
  Sponsor:   University of California, San Diego
  Recruiting
• Sleep Disordered Breathing in Acute Congestive Heart Failure

  NCT03804827

  Conditions:   Obstructive Sleep Apnea;   Heart Failure; With Decompensation
  Intervention:  
  Sponsor:   University of California, San Diego
  Recruiting
• Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

  NCT03693040

  Condition:   HIV Prevention
  Intervention:   Device: Digital Health Feedback System
  Sponsors:   University of California, San Diego;   National Institute of Mental Health (NIMH);   Gilead Sciences;   Proteus Digital Health, Inc.
  Recruiting
• Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

  NCT03611595

  Condition:   Solid Tumor
  Interventions:   Drug: Cabozantinib;   Drug: 13-cis-retinoic acid
  Sponsors:   Peter Zage;   Exelixis
  Recruiting
• Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy

  NCT02800655

  Condition:   HIV
  Intervention:   Device: Digital Health Feedback System
  Sponsors:   University of California, San Diego;   National Institute of Mental Health (NIMH);   Gilead Sciences;   ViiV Healthcare;   GlaxoSmithKline;   Proteus Digital Health, Inc.
  Recruiting
• Improving Office Based Treatment of Opioid Use Disorder With Technology

  NCT03586466

  Condition:   Opioid-use Disorder
  Interventions:   Device: BupreCare;   Drug: Buprenorphine/naloxone;   Other: MEMS
  Sponsors:   MedicaSafe, Inc.;   Friends Research Institute, Inc.
  Recruiting
• Evaluating the Use of Peer Specialists to Deliver Cognitive Behavioral Social Skills Training

  NCT03467243

  Condition:   Serious Mental Illness
  Interventions:   Behavioral: Cognitive Behavioral Social Skills Training;   Behavioral: Social Skills Training;   Behavioral: Treatment as usual
  Sponsor:   VA Office of Research and Development
  Recruiting
• Cognitive Rehabilitation Therapy for Mild Cognitive Impairment

  NCT03225482

  Condition:   Mild Cognitive Impairment
  Interventions:   Behavioral: Motivationally Enhanced Compensatory Cognitive Training;   Behavioral: Goal-focused Supportive Contact
  Sponsors:   VA Office of Research and Development;   Portland VA Medical Center
  Recruiting
• Self-management of Blood Pressure Medication for Hypertensive Veterans

  NCT03224624

  Condition:   Hypertension
  Intervention:   Other: self-management protocol for hypertension care
  Sponsor:   VA Office of Research and Development
  Recruiting
• Text Messaging to Engage and Retain Veterans in Smoking Cessation Counseling

  NCT03177265

  Condition:   Nicotine Dependence
  Interventions:   Behavioral: Text messaging prior to first counseling call;   Behavioral: Text-to-Enhance;   Behavioral: Mail Notice;   Behavioral: Telephone Counseling
  Sponsor:   VA Office of Research and Development
  Recruiting
• Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF

  NCT02456233

  Condition:   Atrial Fibrillation
  Interventions:   Procedure: Conventional AF Ablation with PVI;   Procedure: FIRM-guided ablation plus PVI
  Sponsor:   Stanford University
  Recruiting
• Chronic Low Back Pain and Meditation

  NCT04034004

  Condition:   Pain
  Interventions:   Behavioral: Mindfulness;   Drug: Naloxone;   Other: Saline;   Behavioral: Meditation
  Sponsor:   University of California, San Diego
  Recruiting
• Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight

  NCT04002440

  Conditions:   Efficacy;   Safety Issues
  Interventions:   Combination Product: AMIA with SHARESOURCE Connectivity Platform;   Device: HomeChoice PRO
  Sponsors:   University of California, San Diego;   Baxter Healthcare Corporation;   Scripps Health;   Home Dialysis Therapies of San Diego
  Recruiting
• HTX-011 Administration Study in Planned Caesarean Section Procedure

  NCT03955211

  Condition:   Analgesia
  Interventions:   Drug: HTX-011;   Device: Luer lock applicator
  Sponsor:   Heron Therapeutics
  Recruiting
• Paracervical Block Volume and Pain Control During Dilation and Curettage

  NCT03636451

  Conditions:   Abortion, Spontaneous;   Abortion in First Trimester;   Pain Uterus
  Interventions:   Drug: 0.5% Lidocaine;   Drug: 1% Lidocaine
  Sponsors:   University of California, San Diego;   Society of Family Planning
  Recruiting
• Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas

  NCT03429166

  Condition:   PTSD
  Interventions:   Behavioral: STAIR;   Behavioral: PCT
  Sponsors:   VA Office of Research and Development;   San Diego Veterans Healthcare System
  Recruiting
• Trial to Reduce Sitting Time in Postmenopausal Latina Women at Increased Risk for Heart Disease

  NCT02905929

  Condition:   Sedentary Lifestyle
  Interventions:   Device: ActivPAL inclinometer;   Behavioral: Phone counseling call: Breaking up sitting time;   Behavioral: In-person counseling: Breaking up sitting time;   Behavioral: Phone counseling call: Healthy living;   Other: Tools to prompt standing;   Behavioral: In-person counseling: Healthy living
  Sponsors:   University of California, San Diego;   South Bay Latino Research Center;   San Ysidro Health Center;   San Diego State University
  Recruiting
• Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

  NCT03992729

  Condition:   Pregnancy Related
  Interventions:   Drug: Pregnant women exposed to tildrakizumab;   Drug: Pregnant women not exposed to tildrakizumab
  Sponsor:   Sun Pharma Global FZE
  Recruiting
• Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE)

  NCT03980886

  Condition:   Eosinophilic Esophagitis
  Intervention:  
  Sponsors:   University of California, San Diego;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• Mindful Action for Pain

  NCT03800654

  Condition:   Chronic Pain
  Interventions:   Behavioral: Mindful Action for Pain;   Behavioral: Cognitive Behavioral Therapy for Chronic Pain
  Sponsor:   VA Office of Research and Development
  Recruiting
• Benralizumab Pregnancy Exposure Study

  NCT03794999

  Condition:   Asthma
  Interventions:   Drug: Benralizumab-exposure;   Drug: Exposure to other asthma medications
  Sponsors:   AstraZeneca;   University of California, San Diego, Department of Pediatrics
  Recruiting
• Antibiotic Prophylaxis With Routine Ureteral Stent Removal

  NCT02944825

  Conditions:   Urolithiasis;   UTI
  Interventions:   Drug: Ciprofloxacin;   Drug: trimethoprim/sulfamethoxazole;   Drug: No Intervention
  Sponsors:   University of California, San Diego;   Genesis HealthCare
  Recruiting
• Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2

  NCT02829060

  Conditions:   Nephrolithiasis;   Urinary Tract Infection (UTI);   Sepsis
  Interventions:   Drug: Nitrofurantoin 100 MG, 7d;   Drug: Gentamicin, 5mg/kg;   Drug: Ampicillin 2g;   Drug: Nitrofurantoin 100 mg, 48 hrs;   Drug: Gentamicin, 80 mg, 7d;   Drug: Gentamicin, 80 mg, 48hr
  Sponsor:   University of California, San Diego
  Recruiting
• VDOT for Monitoring Adherence to LTBI Treatment

  NCT02641106

  Conditions:   Tuberculosis;   Latent Tuberculosis Infection
  Interventions:   Other: Video Directly Observed Therapy;   Other: In-Person DOT
  Sponsor:   University of California, San Diego
  Recruiting
• OTIS Autoimmune Diseases in Pregnancy Project

  NCT01797224

  Conditions:   Crohn's Disease;   Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis;   Psoriasis
  Intervention:  
  Sponsors:   University of California, San Diego;   The Organization of Teratology Information Specialists;   UCB Pharma
  Recruiting
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

  NCT04106167

  Conditions:   Advanced Solid Tumor;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small-cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
  Intervention:   Genetic: Allogeneic natural killer (NK) cell
  Sponsor:   Fate Therapeutics
  Recruiting
• Phase I Trial HIPEC With Nal-irinotecan

  NCT04088786

  Conditions:   Peritoneal Cancer;   Pseudomyxoma Peritonei;   Mucinous Adenocarcinoma;   Mucinous Tumor;   Colorectal Cancer;   Gastric Cancer;   Primary Peritoneal Carcinoma;   Mesothelioma
  Intervention:   Drug: nanoliposomal irinotecan
  Sponsors:   Stony Brook University;   University of Kentucky;   University of San Diego
  Recruiting
• Telehealth Intervention for Improved Blood Pressure Control With Targeted Incentives

  NCT04075045

  Conditions:   Hypertension;   Non-Adherence, Patient
  Interventions:   Behavioral: Wellth Smartphone App;   Behavioral: Targeted Incentives;   Behavioral: Non-Restricted Incentives
  Sponsors:   Wellth Inc.;   University of California, San Diego
  Recruiting
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

  NCT03841110

  Conditions:   Advanced Solid Tumors;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
  Interventions:   Drug: FT500;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab;   Drug: Cyclophosphamide;   Drug: Fludarabine
  Sponsor:   Fate Therapeutics
  Recruiting
• Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

  NCT03765450

  Condition:   Ulcerative Colitis
  Intervention:   Drug: Infliximab
  Sponsor:   Robarts Clinical Trials Inc.
  Recruiting
• Remote Sleep Apnea Management

  NCT03007745

  Conditions:   Sleep Apnea - Obstructive;   Cost Effectiveness;   Telemedicine
  Intervention:   Device: autoadjusting continuous positive airway pressure
  Sponsor:   VA Office of Research and Development
  Recruiting
• Collaborative Care for Women Veterans

  NCT02950961

  Conditions:   Anxiety;   Depression;   Stress Disorders, Post Traumatic
  Intervention:   Behavioral: Collaborative Care for Women Veterans
  Sponsor:   VA Office of Research and Development
  Recruiting
• Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms

  NCT04182659

  Conditions:   Gulf War Syndrome;   Gulf War Illness;   Headache;   Muscle Pain;   Joint Pain
  Interventions:   Device: Transcranial Magnetic Stimulation;   Device: Sham Transcranial Magnetic Stimulation
  Sponsors:   Veterans Medical Research Foundation;   United States Department of Defense
  Recruiting
• Clinical Evaluation of the Connected Catheter - Wireless Urinary Prosthesis for Management of Chronic Urinary Retention

  NCT04059159

  Conditions:   Neurogenic Bladder;   Urinary Retention;   Urologic Diseases
  Intervention:   Device: Connected Catheter
  Sponsors:   Spinal Singularity;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• rTMS in Alleviating Pain and Co-Morbid Symptoms in Gulf War Veterans Illness (GWVI)

  NCT04046536

  Conditions:   Gulf War Illness;   Depression
  Interventions:   Device: Transcranial Magnetic Stimulation;   Device: Sham Transcranial Magnetic Stimulation
  Sponsor:   VA Office of Research and Development
  Recruiting
• Early vs. Interval Postpartum IUD Insertion

  NCT03462758

  Condition:   Contraception
  Intervention:   Device: IUD
  Sponsors:   University of California, San Diego;   University of New Mexico;   United States Naval Medical Center, San Diego
  Recruiting
• Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

  NCT03984747

  Conditions:   Kidney Transplant Rejection;   Allograft Rejection;   Kidney Transplant; Complications
  Intervention:  
  Sponsor:   Natera, Inc.
  Recruiting
• Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

  NCT02187133

  Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma
  Interventions:   Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Rituximab
  Sponsors:   University of California, San Francisco;   National Comprehensive Cancer Network
  Recruiting
• Comprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery

  NCT03894423

  Conditions:   CAD;   Atheroscleroses, Coronary;   Computed Tomography;   Coronary Artery Bypass
  Intervention:  
  Sponsors:   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   University of California, San Diego;   VA Palo Alto Health Care System
  Recruiting
• A Healthy Relationships Program for Vulnerable Youth

  NCT03736876

  Conditions:   Pregnancy, Unplanned;   Sexually Transmitted Diseases
  Intervention:   Behavioral: About Us
  Sponsors:   ETR Associates;   Family and Youth Services Bureau;   San Diego State University;   California School-Based Health Alliance
  Recruiting
• A Real World, Multicenter, Open-Label Study to Assess the Effectiveness of, and Satisfaction With, CCH Treatment of Cellulite in Adult Females

  NCT04170296

  Conditions:   Edematous Fibrosclerotic Panniculopathy (EFP);   Cellulite
  Intervention:   Drug: EN3835
  Sponsor:   Endo Pharmaceuticals
  Recruiting
• Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

  NCT03672487

  Condition:   Chagas Disease
  Interventions:   Drug: Benznidazole;   Drug: Placebo Oral Tablet
  Sponsors:   Tulane University School of Public Health and Tropical Medicine;   Institute for Clinical Effectiveness and Health Policy;   University of California, San Diego
  Recruiting
• Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

  NCT04042740

  Conditions:   Hepatitis C Infection;   HIV Infection
  Interventions:   Drug: Glecaprevir/Pibrentasvir (G/P);   Drug: Ribavirin (RBV)
  Sponsors:   AIDS Clinical Trials Group;   AbbVie;   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

  NCT03319459

  Conditions:   HER2 Positive Gastric Cancer;   Colorectal Cancer;   Head and Neck Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   Advanced Solid Tumors;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreatic Cancer;   Melanoma
  Interventions:   Drug: FATE-NK100;   Drug: Cetuximab;   Drug: Trastuzumab
  Sponsor:   Fate Therapeutics
  Recruiting
• Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure

  NCT03056157

  Conditions:   Post-traumatic Stress Disorder;   Moral Injury;   Traumatic Loss
  Interventions:   Behavioral: Adaptive Disclosure for Moral Injury and Loss;   Behavioral: Present Centered Therapy
  Sponsors:   VA Office of Research and Development;   Minneapolis Veterans Affairs Medical Center;   San Francisco Veterans Affairs Medical Center;   San Diego Veterans Healthcare System
  Recruiting
• A Phase 3 Trial of Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

  NCT04124614

  Condition:   Post Traumatic Stress Disorder
  Interventions:   Drug: Brexpiprazole;   Drug: Sertraline;   Other: Placebo
  Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
  Recruiting
• Safety and Tolerability of PNT001 in Healthy Adults

  NCT04096287

  Condition:   Healthy
  Interventions:   Biological: PNT001;   Drug: Placebo
  Sponsor:   Pinteon Therapeutics, Inc
  Recruiting
• Study of Personalized Cancer Therapy to Determine Response and Toxicity

  NCT02478931

  Condition:   Cancer
  Intervention:  
  Sponsor:   Razelle Kurzrock, MD
  Recruiting
• A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects

  NCT03328507

  Condition:   Colonoscopy
  Interventions:   Drug: BLI4900;   Drug: PEG Control
  Sponsor:   Braintree Laboratories
  Recruiting
• Mature B-Cell Lymphoma And Leukemia Study III

  NCT01046825

  Condition:   Mature B-Cell Lymphoma
  Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
  Sponsor:   St. Jude Children's Research Hospital
  Recruiting
• Safety and Efficacy Study of MT-2990 in Women With Endometriosis

  NCT03840993

  Condition:   Endometrial Related Pain
  Interventions:   Drug: MT-2990;   Drug: Placebo
  Sponsor:   Mitsubishi Tanabe Pharma Development America, Inc.
  Recruiting
• Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

  NCT03951077

  Condition:   Polycystic Ovary Syndrome
  Interventions:   Drug: Elagolix;   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

  NCT03886220

  Condition:   Uterine Fibroids
  Interventions:   Drug: Elagolix;   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

  NCT03745820

  Conditions:   Cognitive Impairment Associated With Schizophrenia;   Schizophrenia
  Interventions:   Drug: BIIB104;   Other: Placebo
  Sponsor:   Biogen
  Recruiting
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia

  NCT03593213

  Condition:   Schizophrenia
  Interventions:   Drug: Cariprazine;   Drug: Placebo
  Sponsor:   Forest Laboratories
  Recruiting
• Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

  NCT04131036

  Condition:   Hemophilia A
  Intervention:   Other: assessment of joint health and bone density
  Sponsors:   Bloodworks;   Genentech, Inc.
  Recruiting
• SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

  NCT03204318

  Condition:   Endometriosis Related Pain
  Interventions:   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate;   Drug: Placebo for E2/NETA;   Drug: Placebo for relugolix
  Sponsor:   Myovant Sciences GmbH
  Recruiting
• Work Ability in Young Adult Cancer Survivors

  NCT03148080

  Condition:   Cancer Survivor
  Interventions:   Procedure: Cognitive Assessment;   Other: Questionnaire Administration
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• BEACH Trial: Bovine Early Access, Compatibility and Hemostasis Trial

  NCT04146012

  Condition:   Renal Insufficiency,Chronic
  Intervention:   Device: Artegraft® Collagen Vascular Graft™ (Artegraft)
  Sponsor:   Artegraft, Inc.
  Recruiting
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT02744612

  Conditions:   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Ibrutinib
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain

  NCT03263611

  Condition:   Degenerative Disc Disease
  Interventions:   Drug: Placebo;   Drug: AMG0103
  Sponsor:   AnGes, Inc.
  Recruiting
• Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

  NCT01766297

  Conditions:   Breast Cancer;   Breast Neoplasm;   Breast Tumor;   Cancer of the Breast
  Intervention:   Radiation: Proton Radiotherapy
  Sponsor:   Proton Collaborative Group
  Recruiting
• A Study to Assess PV-10 Chemoablation of Cancer of the Liver

  NCT00986661

  Conditions:   Cancer Metastatic to the Liver;   Hepatocellular Carcinoma;   Metastatic Melanoma;   Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma;   Metastatic Lung Cancer;   Metastatic Colon Cancer;   Metastatic Colorectal Cancer;   Metastatic Breast Cancer;   Metastatic Pancreatic Cancer
  Intervention:   Drug: PV-10 (10% rose bengal disodium)
  Sponsor:   Provectus Biopharmaceuticals, Inc.
  Recruiting
• Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

  NCT01492972

  Condition:   Prostate Cancer
  Interventions:   Radiation: Radiation;   Drug: Androgen Suppression Therapy
  Sponsor:   Proton Collaborative Group
  Recruiting
• CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

  NCT03904251

  Condition:   Acute Myelogenous Leukemia
  Interventions:   Drug: Gemtuzumab Ozogamicin;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine
  Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

  NCT02553941

  Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Myelodysplastic Syndrome
  Interventions:   Drug: Azacitidine;   Drug: Ibrutinib
  Sponsors:   Brian Jonas;   Pharmacyclics LLC.
  Recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

  NCT02118584

  Condition:   Ulcerative Colitis
  Intervention:   Drug: Etrolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

  NCT03148795

  Condition:   Prostate Cancer
  Intervention:   Drug: Talazoparib
  Sponsors:   Pfizer;   Medivation, Inc.
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis

  NCT01500551

  Condition:   Juvenile Idiopathic Arthritis
  Intervention:   Drug: Tofacitinib
  Sponsor:   Pfizer
  Recruiting
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

  NCT04003389

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

  NCT03969719

  Condition:   Non-alcoholic Steatohepatitis
  Interventions:   Drug: Placebo;   Drug: PF-06835919
  Sponsor:   Pfizer
  Recruiting
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

  NCT03901482

  Conditions:   Migraine;   Migraine With Aura;   Migraine Without Aura
  Interventions:   Drug: Dihydroergotamine;   Drug: Placebos
  Sponsor:   Satsuma Pharmaceuticals, Inc.
  Recruiting
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
  Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION]

  NCT03616821

  Conditions:   Colitis;   Ulcerative;   IBD
  Interventions:   Drug: Brazikumab;   Drug: Vedolizumab;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223

  Condition:   Acute Coronary Syndrome
  Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
  Sponsor:   CSL Behring
  Recruiting
• AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

  NCT03028740

  Condition:   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Cenicriviroc;   Drug: Placebo
  Sponsor:   Tobira Therapeutics, Inc.
  Recruiting
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

  NCT02958865

  Condition:   Ulcerative Colitis
  Interventions:   Drug: PF-06651600 or Placebo;   Drug: PF-06700841 or Placebo;   Drug: PF-06700841;   Drug: PF-06651600
  Sponsor:   Pfizer
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

  NCT02744092

  Conditions:   Cancer;   Venous Thromboembolism;   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Blood Clot
  Interventions:   Drug: Rivaroxaban;   Drug: Apixaban;   Drug: Edoxaban;   Drug: Dabigatran;   Drug: Warfarin;   Drug: Dalteparin;   Drug: Enoxaparin;   Drug: Fondaparinux
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132

  Condition:   Agitation in Patients With Dementia of the Alzheimer's Type
  Intervention:   Drug: AVP-786
  Sponsor:   Avanir Pharmaceuticals
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Psoriasis Longitudinal Assessment and Registry (PSOLAR)

  NCT00508547

  Conditions:   Psoriasis;   Arthritis, Psoriatic
  Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
  Sponsor:   Janssen Scientific Affairs, LLC
  Recruiting
• Dysport in Vulvodynia Phase II Study

  NCT03598777

  Condition:   Vulvodynia
  Interventions:   Biological: Botulinum toxin type A;   Drug: Placebo
  Sponsor:   Ipsen
  Recruiting
• A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

  NCT02994953

  Condition:   Advanced Solid Tumors
  Interventions:   Drug: Avelumab;   Drug: M9241;   Drug: Avelumab (Once weekly);   Drug: M9241 (MTD);   Drug: Avelumab (Expansion cohort)
  Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
  Recruiting
• A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

  NCT03517566

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: ZPL389
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

  NCT03893682

  Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Non-Hodgkin's Lymphoma
  Intervention:   Drug: CG-806
  Sponsor:   Aptose Biosciences Inc.
  Recruiting
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT03631706

  Condition:   Non-small Cell Lung Cancer
  Interventions:   Drug: M7824;   Drug: Pembrolizumab
  Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
  Recruiting
• A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease

  NCT03887455

  Condition:   Early Alzheimer's Disease
  Interventions:   Drug: BAN2401;   Drug: Placebo
  Sponsors:   Eisai Inc.;   Biogen
  Recruiting
• A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

  NCT03598790

  Conditions:   Chronic Plaque Psoriasis;   Moderate to Severe Chronic Plaque Psoriasis
  Intervention:   Drug: Bimekizumab
  Sponsor:   UCB Biopharma S.P.R.L.
  Recruiting
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

  NCT04003142

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474

  Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

  NCT03895372

  Condition:   Psoriasis
  Interventions:   Drug: PF-06826647 or Placebo;   Drug: PF-06826647
  Sponsor:   Pfizer
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

  NCT03806127

  Condition:   Irritable Bowel Syndrome
  Interventions:   Drug: Vibegron;   Drug: Placebo
  Sponsor:   Urovant Sciences GmbH
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

  NCT03762850

  Condition:   Immunoglobulin A Nephropathy
  Interventions:   Drug: sparsentan;   Drug: irbesartan
  Sponsor:   Retrophin, Inc.
  Recruiting
• A Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

  NCT03759041

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Vancomycin Pre-Treatment;   Drug: Placebo for Vancomycin Pre-Treatment;   Drug: SER-287;   Drug: Placebo for SER-287
  Sponsor:   Seres Therapeutics, Inc.
  Recruiting
• Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

  NCT03737994

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928

  Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
  Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

  NCT03701282

  Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep

  NCT03679884

  Condition:   Insomnia Disorder
  Interventions:   Drug: ACT-541468 10 mg;   Drug: ACT-541468 25 mg;   Drug: ACT-541468 50 mg;   Drug: Placebo
  Sponsor:   Idorsia Pharmaceuticals Ltd.
  Recruiting
• Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)

  NCT03624881

  Condition:   Paroxysmal Atrial Fibrillation
  Intervention:   Device: Catheter ablation with EPU
  Sponsor:   Biosense Webster, Inc.
  Recruiting
• Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

  NCT03587805

  Condition:   Atopic Dermatitis
  Intervention:   Drug: Tralokinumab
  Sponsor:   LEO Pharma
  Recruiting
• A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

  NCT03573297

  Conditions:   Bipolar I Disorder;   Mania;   Depression
  Interventions:   Drug: Cariprazine;   Drug: Placebo
  Sponsor:   Forest Laboratories
  Recruiting
• Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

  NCT03569007

  Condition:   Celiac Disease
  Interventions:   Drug: Larazotide;   Drug: Matching Placebo
  Sponsor:   Innovate Biopharmaceuticals
  Recruiting
• A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

  NCT03561090

  Condition:   Gastroesophageal Reflux Disease (GERD)
  Interventions:   Drug: IW-3718;   Drug: placebo
  Sponsor:   Ironwood Pharmaceuticals, Inc.
  Recruiting
• Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

  NCT03457896

  Condition:   Metastatic Colorectal Cancer
  Interventions:   Drug: Trastuzumab;   Drug: Cetuximab;   Drug: Neratinib;   Diagnostic Test: Guardant360 Diagnostic Test
  Sponsors:   NSABP Foundation Inc;   Puma Biotechnology, Inc.
  Recruiting
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

  NCT03383146

  Conditions:   Gastroparesis;   Diabetes Mellitus
  Interventions:   Drug: Relamorelin;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

  NCT03345849

  Condition:   Crohn's Disease
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

  NCT03345836

  Condition:   Crohn's Disease
  Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

  NCT03285308

  Conditions:   Gastroparesis;   Diabetes Mellitus
  Interventions:   Drug: Relamorelin;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

  NCT03281954

  Condition:   Triple Negative Breast Cancer
  Interventions:   Drug: Placebo;   Drug: Atezolizumab
  Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

  NCT03121586

  Condition:   Schizophrenia
  Intervention:   Drug: Pimavanserin
  Sponsor:   ACADIA Pharmaceuticals Inc.
  Recruiting
• MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

  NCT03072927

  Condition:   Lumbar Spinal Stenosis
  Intervention:   Device: MILD
  Sponsor:   Vertos Medical, Inc.
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

  NCT02997228

  Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)

  NCT02163759

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Adalimumab;   Other: Adalimumab Placebo;   Drug: Etrolizumab;   Other: Etrolizumab Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

  NCT02876835

  Condition:   Anaemia
  Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
  Sponsor:   GlaxoSmithKline
  Recruiting
• Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

  NCT02855164

  Condition:   Non-alcoholic Steatohepatitis (NASH)
  Interventions:   Drug: Tropifexor (LJN452);   Drug: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

  NCT02782104

  Condition:   Depressive Disorder, Treatment-Resistant
  Intervention:   Drug: Esketamine Nasal Spray
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

  NCT02565511

  Condition:   Alzheimer's Disease
  Interventions:   Biological: CAD106 Immunotherapy;   Other: Placebo to CAD106;   Drug: CNP520;   Other: Placebo to CNP520
  Sponsors:   Novartis Pharmaceuticals;   Banner Alzheimer's Institute;   National Institute on Aging (NIA);   Alzheimer's Association;   Amgen
  Recruiting
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

  NCT02554812

  Condition:   Advanced Cancer
  Interventions:   Drug: Avelumab;   Drug: Utomilumab;   Drug: PF-04518600;   Drug: PD 0360324;   Drug: CMP-001
  Sponsor:   Pfizer
  Recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

  NCT03914625

  Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
  Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561

  Condition:   Ulcerative Colitis (UC)
  Intervention:  
  Sponsor:   AbbVie
  Recruiting
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

  NCT03155620

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592

  Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994

  Condition:   Leukemia
  Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Incyte Corporation;   Children's Oncology Group
  Recruiting
• S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881

  Condition:   Colorectal Neoplasms
  Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
  Recruiting
• Multi-center Study to Validate niPGT-A

  NCT03520933

  Conditions:   Aneuploidy;   Chromosome Abnormality;   Infertility
  Interventions:   Diagnostic Test: PGT-A;   Diagnostic Test: niPGT-A
  Sponsor:   Igenomix
  Recruiting
• Comparison of MENOPUR Liquid and Powder in Women Undergoing ART

  NCT04163458

  Condition:   Infertility
  Interventions:   Drug: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL;   Drug: MENOPUR powder and solvent for solution for injection, 75 IU;   Other: Placebo (for MENOPUR solution for injection in pre-filled pen);   Other: Placebo (for MENOPUR powder and solvent for solution for injection)
  Sponsor:   Ferring Pharmaceuticals
  Recruiting
• Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation

  NCT04035200

  Condition:   Insomnia
  Interventions:   Drug: V117957 tablets;   Drug: Placebo
  Sponsor:   Imbrium Therapeutics
  Recruiting
• The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

  NCT03775200

  Condition:   Treatment Resistant Depression
  Intervention:   Drug: Psilocybin
  Sponsor:   COMPASS Pathways
  Recruiting
• A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

  NCT03714152

  Condition:   Chronic Hepatitis B
  Interventions:   Drug: ABI-H2158;   Drug: Placebo for ABI-H2158
  Sponsor:   Assembly Biosciences
  Recruiting
• Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

  NCT02932475

  Conditions:   Diabetes;   Pregnancy
  Interventions:   Drug: Metformin;   Drug: Placebo
  Sponsors:   University of North Carolina, Chapel Hill;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

  NCT03642210

  Condition:   Menorrhagia
  Intervention:   Combination Product: Levonorgestrel 52 mg intrauterine system
  Sponsor:   Medicines360
  Recruiting
• Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

  NCT02308085

  Condition:   Early Breast Cancer
  Intervention:   Other: Endocrine therapy interruption
  Sponsors:   International Breast Cancer Study Group;   Alliance for Clinical Trials in Oncology;   Canadian Cancer Trials Group;   Breast International Group
  Recruiting
• Short-term Clinical Deterioration After Acute Pulmonary Embolism

  NCT03915925

  Condition:   Pulmonary Embolism
  Intervention:  
  Sponsors:   Atrium Health;   Agency for Healthcare Research and Quality (AHRQ)
  Recruiting
• A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia

  NCT03771664

  Conditions:   Major Depressive Disorder;   Insomnia
  Interventions:   Drug: SAGE-217;   Drug: Placebo
  Sponsor:   Sage Therapeutics
  Recruiting
• Longitudinal Performance of Epi proColon

  NCT03218423

  Conditions:   Colorectal Cancer;   Colorectal Neoplasms
  Intervention:   Device: Epi proColon
  Sponsor:   Epigenomics, Inc
  Recruiting
• A Study to Assess the Effects of RO6889450 in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

  NCT03669640

  Condition:   Schizophrenia, Schizoaffective Disorder
  Interventions:   Drug: RO6889450;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)

  NCT03654326

  Condition:   Endometriosis-related Pain
  Interventions:   Drug: Gefapixant;   Drug: Placebo;   Drug: Naproxen
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

  NCT03500328

  Condition:   Multiple Sclerosis, Relapsing-Remitting
  Intervention:   Other: Early Aggressive Therapy or Traditional Therapy
  Sponsors:   Johns Hopkins University;   Patient-Centered Outcomes Research Institute
  Recruiting
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

  NCT03896945

  Condition:   Schizophrenia
  Interventions:   Drug: Placebo;   Drug: AVP-786
  Sponsor:   Avanir Pharmaceuticals
  Recruiting
• A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia

  NCT03382639

  Condition:   Schizophrenia
  Interventions:   Drug: TAK-831;   Drug: Placebo
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting